Broadening Versant’s obesity portfolio, Antag plots clinical path with €80M

After seven years subsisting on seed capital, Antag has attracted a series A round that will support clinical testing of a GIPR antagonist, the first human test of a thesis that a standalone peptide aimed at that target can become a useful tool in an evolving marketplace for obesity therapies.

Versant Ventures, which is building a portfolio of obesity therapies that Managing Director Alex Mayweg called its “Beyond Ozempic” strategy, led the €80 million ($83.9 million) for Copenhagen-based Antag Therapeutics ApS...